Literature DB >> 20524443

The bioequivalent and effect of nicotine formulation gum on smoking cessation.

Yongyuth Tundulawessa1, Praparn Yongchaiyud, Waradoon Chutrthong, Kavita Tundulawessa.   

Abstract

OBJECTIVE: To compare the absorption rate of nicotine in volunteer blood, and determine the clinical trial on smoking cessation. MATERIAL AND
METHOD: This method using reverse phase C18 column and buffer pH 5.05 as the mobile phase, flow rate 0.9 ml/min. The UV-visible detector found the retention time of nicotine in gum and volunteer blood was 5.0756 min. The linear calibration curves of nicotine in human blood were obtained over the concentration range of 2.0-20.0 microg/ml. The coefficient variability for Nicotine gum 6.74% (2 mg/g). Extraction recovery was over 86% in blood, correlation coefficient of determination (r2) > 0.9999 and the detection limit 0.0060 microg/ml. The 24 healthy volunteer men, 27 to 55 years of age, were habitual cigarette smokers. They were randomized into two groups, 12 subjects chewed two 2 mg pieces, Nicomild-2 Sugar Free Gum (Millimed, Thailand), the other chewed two 2 mg, pieces, Nicorette Sugar Free (Pharmacia AB, Helsingborg, Sweden.) Volunteers' blood samples were withdrawn at 0, 15, 30, 40 min, concentration of nicotine in blood were measured by HPLC. The 199 subjects were openly recruited under the project of "The smoking cessation for Phor Laung" (5-December). All of them received Nicomild-2 (nicotine polyestex gum) between November 2007 and December 2007.
RESULTS: The absorption rate of nicotine in volunteers' blood Nicomild-2 and Nicorette at 0, 15, 30, 40 minutes were 0, 51.84, 26.73, 21.012 and 0, 56.603, 21.83, 15.183 (ng/min). Both of them were found to have maximum absorption rate at 15 minutes. When comparing the maximum absorption rate at 15 minute of Nicomild-2 (sugar free) with Nicorette (sugar free) didn't have significant differences detected. Treatment with nicotine polyestex gum were reported 65.3% (130/199) at 4 weeks compared with failure 30.15% (60/199)[ 65.3% vs 30.15%; p = 0.005]. The authors found 9 (4.5%) subjects successfully quit smoking free nicotine replacement therapy (NRT).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524443

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  5 in total

1.  Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.

Authors:  Nicola Lindson; Samantha C Chepkin; Weiyu Ye; Thomas R Fanshawe; Chris Bullen; Jamie Hartmann-Boyce
Journal:  Cochrane Database Syst Rev       Date:  2019-04-18

2.  Activation of AMP-activated protein kinase α2 by nicotine instigates formation of abdominal aortic aneurysms in mice in vivo.

Authors:  Shuangxi Wang; Cheng Zhang; Miao Zhang; Bin Liang; Huaiping Zhu; Jiyeon Lee; Benoit Viollet; Lijun Xia; Yun Zhang; Ming-Hui Zou
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

Review 3.  Nicotine replacement therapy versus control for smoking cessation.

Authors:  Jamie Hartmann-Boyce; Samantha C Chepkin; Weiyu Ye; Chris Bullen; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2018-05-31

4.  Activation of AMPKα2 in adipocytes is essential for nicotine-induced insulin resistance in vivo.

Authors:  Yue Wu; Ping Song; Wencheng Zhang; Junhui Liu; Xiaoyan Dai; Zhaoyu Liu; Qiulun Lu; Changhan Ouyang; Zhonglin Xie; Zhengxing Zhao; Xiaozhen Zhuo; Benoit Viollet; Marc Foretz; Jiliang Wu; Zuyi Yuan; Ming-Hui Zou
Journal:  Nat Med       Date:  2015-03-23       Impact factor: 53.440

5.  Evidence-based new service package vs. routine service package for smoking cessation to prevent high risk patients from cardiovascular diseases (CVD): study protocol for randomized controlled trial.

Authors:  Myo Nyein Aung; Motoyuki Yuasa; Thaworn Lorga; Saiyud Moolphate; Hiroshi Fukuda; Tsutomu Kitajima; Hirohide Yokokawa; Kazuo Minematsu; Susumu Tanimura; Yoshimune Hiratsuka; Koichi Ono; Prissana Naunboonruang; Payom Thinuan; Sachio Kawai; Yaoyanee Suya; Somboon Chumvicharana; Eiji Marui
Journal:  Trials       Date:  2013-12-05       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.